

Swiss compulsory health insurance reimburses Ameluz® for treatment of actinic keratosis

- **Inclusion in reimbursement list of Swiss Federal Office of Public Health**
- **Treatment of actinic keratosis (AK) to be reimbursed with immediate effect**

Leverkusen, Germany, March 31, 2016 – Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, today announced that the Swiss Federal Office of Public Health has included Ameluz® in its reimbursement list after a thorough examination of its effectiveness and efficiency. This marks another successful event in the Company's efforts towards international commercialization of Ameluz®. Following this, the Swiss compulsory health insurance (KVG) will cover the cost for the photodynamic treatment of actinic keratosis (AK) with Ameluz® with immediate effect. Insurance with KVG is generally mandatory for everyone living in Switzerland. Biofrontera's Swiss marketing partner, Louis Widmer S.A., received the marketing authorization for Ameluz® in December 2015, and now with recent reimbursement status, Ameluz® will be launched on the Swiss market through Louis Widmer in the coming months.

Prof. Hermann Lübbert, CEO of Biofrontera AG commented: "Reimbursement by the Swiss public health insurance is a major step forward for us. This is one more European country – bringing the total to 12 – now offering patients with mild or moderate actinic keratosis the opportunity of treatment with Ameluz® to effectively clear AK skin lesions before they advance to squamous cell carcinoma (SCC), the second most common form of skin cancer. We are pleased with this positive decision of the Swiss Federal Office of Public Health and look forward to supporting Louis Widmer in making Ameluz® widely available to dermatologists and their patients in Switzerland."

Ends

Enquiries, please contact: Biofrontera AG
Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
press@biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker

+49 (0) 152 08931514

IR UK: Seton Services
Toni Vallen

+44(0) 20 7729 0805

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui
PR: Kirsten Thomas

+1 646-536-7012 / 7035
+1 508-280-6592

About Biofrontera

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is **Ameluz®**, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.